Pirfenidone, an anti-inflammatory and anti-fibrotic small molecule approved for the treatment of idiopathic pulmonary fibrosis (IPF), is thought to exert its effects in part by suppressing TGF-β production, although its mechanism of action is not entirely understood. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.